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Abstract
Background: Oxaliplatin induced peripheral neurotoxicity (OXIPN) is the major dose-limiting and long-lasting side
effect of oxaliplatin. N-3 PUFAs have neuroprotective property via their effects on voltage-gated ion channels and
by reducing the production of proinflammatory cytokines that causes neuropathy. This study was a randomized
double blind placebo controlled trial to find the possible advantages of n-3 PUFAs for preventing and reducing the
severity of OXIPN in patients with colon cancer.
Methods: Eligible patients with colon cancer randomly allocated to take n-3 PUFAs pearls, 640 mg t.i.d during
chemotherapy with oxaliplatin and one month after the cessation of the treatment or placebo. All patients were
evaluated for incidence and severity of OXIPN based on “reduced Total Neuropathy Score” in which clinical and
electrophysiological assessments were included.
Results: Seventeen patients (47 %) of the n-3 PUFA supplemented group (n = 36) did not develop PN while it was
11 %(4 patients) in the placebo group (n = 35). There was a significant difference in PN incidence (OR = 0.14, .95 %
CI = (0.04 to 0.49), p = 0.002). The difference of OXIPN severity was significant between the two study groups (B = −1.61,
0.95 % CI = (−2.59 to −0.62), p = 0.001).
Conclusions: N-3 PUFAs may have neuroprotective effect for reducing the incidence and severity of OXIPN. Finding an
effective prophylactic or symptomatic therapy for OXIPN would significantly improve the patients’ quality of life.
Trial registration: IRCT201112158397N2
Keywords: Colon cancer, n-3 polyunsaturated fatty acids, Oxaliplatin, Neuropathy
Background
Colorectal cancer (CRC) is one of the most common
cancers in the world with a considerable mortality rate
and rising incidence during the last decades [1]. Oxali-
platin is now a central choice for treatment of advanced
CRC [2] as the first line chemotherapy regimen [3] and
as adjuvant therapy [4]. However, it induces a peripheral
neuropathy which is the major dose-limiting side effect
of this chemotherapeutic agent. Oxaliplatin-induced per-
ipheral neuropathy (OXIPN) results in an acute transient
syndrome, and a chronic sensory-motor axonal periph-
eral neuropathy. It may be a dose-limiting and disabling
neurotoxicity that continues for a long time [5–8].
Eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) are two main forms of n-3 polyunsaturated fatty
acids (PUFAS). They are structural components of cell
phospholipid membranes including those of the nervous
system [9]. They have beneficial effects on a number of
psychiatric and neurodegenerative diseases [9–11]. At
present, there is no neuroprotective agent for prophy-
laxis and treatment of OXIPN [5, 12, 13], although sev-
eral compounds have been proposed to have some
effects on acute form of OXIPN. We previously reported
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the efficacy of n-3 PUFAs for prophylaxis against
paclitaxel-induced peripheral neuropathy in patients
with breast cancer [14].
The possible advantages of n-3 PUFAs for preventing
and reducing the severity of OXIPN in patients with
colon cancer were assessed in the present study that is
the first attempt in this area. As CRC survivors are the
third largest population of cancer survivors [2, 5, 13],
attenuating the risk of OXIPN- the major factor that
decreases their quality of life- is now a major concern.
Moreover, the serum level of proinflammatory cytokines
was measured for assessing their changes during supple-
mentation with n-3 PUFAs.
Methods
Primary outcome
This randomized double-blind placebo-controlled trial
was conducted to assess the effect of n-3 PUFAs on inci-
dence and severity of OXIPN in patients with colon can-
cer undergoing chemotherapy with oxaliplatin.
Patients
From February 2012 to January 2015, male or female
patients with confirmed stage III colon cancer, aged
between 20 and 85 years, and treated at Sheikhorrais
University Clinic with oxaliplatin, 130 mg/m2 IV, admin-
istered over 2 h infusion in day 1 and oral capecitabine
(1000 mg/m2, b.i.d) on days 1–4, to be repeated every
3 weeks for 8 cycles, were enrolled. Other inclusion
criteria of the study were WHO performance status
score of 0-1, and normal kidney and liver function.
Patients were excluded from the study if they had pre-
existing peripheral neuropathy (PN) due to diabetes
mellitus, alcoholic disease, HIV, and inherited PN- asso-
ciated disorders. Patients who received other neurotoxic
drugs prior to oxaliplatin therapy or those who were on
any form of supplement therapy (fish oil, vitamins and
minerals) were also excluded from the study.
Intervention and randomization
Eligible patients were randomly allocated in a 1:1 ratio
to receive n-3 PUFAs pearls (Mor DHA Mini I.Q. Min-
ami Nutrition NV, Drie Eikenstraat 661, 2650 Edegem,
Belgium) at a dose of 640 mg (54 % DHA, 10 % EPA)
three times a day coinciding with the start of chemother-
apy until one month after the end of treatment or pla-
cebo pearls containing sun flower oil (Dana Pharma,
Tabriz, Iran). Placebo and n-3 PUFAs pearls were similar
in appearance and color and administered based on the
same protocol.
Random allocation software (RAS) version 1.0.0.
(Esfahan, Iran) was used for Permuted block
randomization to assign patients to either the n-3 PUFAs
supplemented group or the control group. Only the
randomization coordinator of the study was aware of the
patients’ allocations.
Neurologic evaluation
All patients were evaluated prior to chemotherapy and
one month after the cessation of treatment (about
25 weeks) by the same neurologist who carried out both
clinical and electrophysiological assessments. He was
blinded to the patient’s allocation to study groups.
The presence of chronic OXIPN and grading of its se-
verity was ascertained by reduced Total Neuropathy Score
(TNSr) as the primary outcome measures. TNSr is an easy
to use composite scale for assessing chemotherapy-
induced peripheral neuropathy (CIPN) [15]. Subjective
sensory symptoms, pin sensibility, deep tendon reflexes,
and sural and peroneal amplitude (a total of 7 parameters)
are all included in TNSr. Each parameter has a score from
0 to 4, based on the measured severity; then the total score
ranges from 0 to 28 that grades OXIPN as follows: grade
0, no OXIPN, 1–10, mild; 11–19, moderate; and 20–28,
severe OXIPN [14].
Secondary outcome
a) Nerve conduction studies (NCVs)
Electrophysiological studies were carried out
unilaterally (right side) under a uniform protocol
using a Nicolet/VIASYS Viking Quest EMG
Machine [16]. Thirty-two to 34°C was set as the
distal skin temperature. The estimated parameters
included: Distal motor latency (DML), peak to
baseline amplitude of compound muscle action
potential (a-CMAP), and motor conduction velocity
for tibial, Peroneal and ulnar nerves. Moreover,
peak-to-peak amplitude of sensory action potentials
(a-SAP) and sensory conduction velocity (antidromic
technique) of sural and ulnar nerves were also
measured.
b) Proinflammatory cytokines
Serum levels of proinflammatory cytokines:
interleukin-6 (IL-6), tumor necrosis factor alpha
(TNF-α), and high-sensitivity C-reactive Protein (hs-
CRP) were measured before the onset of chemother-
apy and one month after the cessation of treatment
by Human IL-6 Platinum ELISA, Human TNF
alpha Platinum ELISA (eBioscience, INC. San
Diego, CA 92121, USA) and Minineph™ Human
kits (Birmingham, UK) respevtively.
Protocol approvals and patient consent
This study (IRCT201112158397N2) was approved by the
Ethics Committee of Tabriz University of Medical
Sciences (No: 5/4/10130) and informed consent was
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obtained from all the study subjects before any
intervention.
Statistical analysis
Data have been shown using mean (SD) and frequency
(percent) for quantitative and qualitative variables re-
spectively. To define the differences of nerve conduction
measurements, analysis of covariance was used adjusting
baseline measurements. Logistic regression analysis was
performed to find the difference of OXIPN incidence be-
tween the two groups, estimating the odds ratio. Ordinal
regression analysis was done to compare the severity of
OXIPN. All tests were two-tailed and significance level
was determined 0.05. For analyzing the results on an
intention to treat (ITT) basis, multiple imputation was
performed by related variables. Statistical power of the
study was 80 % and all analysis was done using spss soft-
ware, (spss Inc., Chicago, IL).
Sample size
To determine the sample size, primary information was
obtained from the study by Ghoreishi et al. In this study,
the protective effect of n-3 PUFAs against paclitaxel-
induced neuropathy in patients with breast cancer was
assessed. Using odds ratio (OR) = 0.3, α = 0.05, a power
of 80 %, and two-tailed analysis and G Power software
(Franz Foal, Kiel University, Germany), the minimum
sample size was estimated 38 subjects and after consid-
ering 30 % lost to follow up, it was increased to 50.
Results
Patients
Among the 84 recruited patients, 13 patients were ex-
cluded from the study due to diabetes mellitus, declined
to participate, and taking some kinds of oral supple-
ments (Fig. 1). Therefore, 71 patient were randomly
allocated to receive n-3 PUFAs (n = 36, 50 % male with
the average of age and BMI as: 54.14 ± 10.53 & 23.47 ±
3.40 kg/m2 respectively) or placebo (n = 35, 60 % male,
with the average of age and BMI as: 53.40 ± 15.70 &
23.22 ± 4.77 kg/m2 respectively). There was not any stat-
istical difference between two groups in terms of gender,
age, and BMI (P = .477, .816, and .806 respectively,
Table 1). The rate of drop out was 5 patients in n-3
PUFAs supplemented group and 7 patients in the pla-
cebo group (Fig. 1), so the response rate was 80.09 %.
Data of the main outcome (incidence and severity of
OXIPN), was divided into 2 categories: code 1 allocated
to missing and code 2 allocated to valid observations.
Then demographic variables were compared between
ITT patients and efficacy population. Accordingly, they
were not statistically different in terms of age (P = 0.658),
BMI (P = 0.224) and gender (P = 0.354).
All patients suffered from metastatic colon cancer
(stage III) and they treated with oxaliplatin, 130 mg/m2
IV, administered over 2 h infusion in day 1 and oral
capecitabine (1000 mg/m2, b.i.d) on days 1–4, to be
repeated every 3 weeks for 8 cycles. No patient received
radiation therapy. The patients of the two groups were
equivalent regarding the treatment protocol.
Assessment of OXIPN
One month after the cessation of chemotherapy, 17 pa-
tients (47 %) did not develop OXIPN in n-3 PUFAs supple-
mented group while the remaining 19 patients manifested
some grade of neurotoxicity based on TNSr: mild OXIPN
in 15(42 %) patients; moderate and severe OXIPN in 1(3 %)
and 3(8 %) patients respectively. In placebo group, OXIPN
was disclosed in 31 (88 %) of the patients: mild OXIPN in
20 patients (57 %), moderate and severe OXIPN in 7 pa-
tients (20 %) and 4 patients (12 %) respectively (Fig. 2). A
significant difference was observed between the two groups
in OXIPN incidence (OR = 0.14, .95 % CI = (0.04 to 0.49),
p = 0.002). So group I had 86 % lower risk of PN incidence.
The number needed to treat (NNT) to prevent one PN
event was 2, and absolute risk reduction(ARR) for supple-
mented group compared with the control group was
0.41(0.16 to 0.59). Remarkably, there were a statistically sig-
nificant difference in severity of OXIPN between these two
groups (B = −1.61, .95 % CI = (−2.59 to −.62), p = 0.001).
Adjusting for age, the differences between incidence and se-
verity of OXIPN were more significant [(OR = 0.11, .95 %
CI = (0.27 to 0.42), p = 0.001); (B = −1.74, .95 % CI = (−2.74
to − .75), p =0.001)].
Nerve conduction studies
Significant statistical changes were observed between
two study groups in terms of tibial and ulnar motor a-
CMAP at one month after the cessation of chemother-
apy (Table 2). However, the percent change measured
(final measures versus the baseline values) showed that
the deterioration of tibial, and ulnar a-CMAP was
considerable in placebo group while they were increased
in the. Moreover, the increase of peroneal nerve a-
CMAP in the n-3 PUFAs group was much more than
the increase in the placebo group (Table 2).
There was not a statistically difference between the
two study groups according to sensory conduction stud-
ies, although a considerable trend for the differences of
sural a-SAPs was observed between the two groups. The
percent change of both sural and ulnar nerves’ a-SAP
showed a considerable decrease however, the decrease of
the a-SAPs was strongly more pronounced in the
placebo group at one month after the cessation of
chemotherapy (Table 3).
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Proinflammatory cytokines
At the end of supplementation period (one month after
the cessation of chemotherapy), the serum levels of IL-6
and TNF-α decreased 20.91 and 12.50 % respectively in
the n-3 PUFAs group while they were increased in the
placebo group without statistically significant differ-
ences. The serum level of hs-CRP was decreased in both
groups although it was further reduced in the placebo
group (61.02 % vs. 55.21 %, Table 4).
Discussion
We assessed the efficacy of n-3 PUFAs, mainly DHA, for
preventing and reducing the severity of OXIPN in pa-
tients with colon cancer. Patients undergoing chemo-
therapy with oxaliplatin (XELOX regimen) randomly
assigned to receive n-3 PUFAs pearls or placebo during
the treatment courses and one month after the cessation
of therapy (about 25 weeks) while incidence and severity
of OXIPN were assessed in both time. This study
showed that n3- PUFAs are protective against OXIPN
in patients with colon cancer. Here we focused solely
on chronic OXIPN that is a sensory- motor axon loss
and the major dose-limiting side effect of oxaliplatin.
It begins at a cumulative dose of 750–850 mg/m2 and
may be continued for a long time after the end of
treatment [7, 17].
Clinical and electrophysiological finding were summa-
rized by TNSr [15, 18] (ranging 0 to 28). It can be easily
used for determining the incidence and severity of CIPN
and it has a significant correlation with the known
oncologic toxicity scales such as NCI-CTC, Ajani and
ECOG scales, and the complete version of TNS as
Fig. 1 Flowdiagram of the study
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well [14, 15]. It is an effective easy-to-use alternative
for TNS.
Nerve conduction studies can assess the extent of
chemotherapy-induced peripheral neuropathy object-
ively and are also capable of identifying patients with
subclinical neuropathy before the manifestation of
clinically significant peripheral neuropathy [19]. In this
study, the a-CMAPs of all three tibial, peroneal and
ulnar motor nerves, were increased in proportion to
the baseline values in the n-3 PUFAs group, while they
decreased in the placebo group (except for peroneal
nerve which also increased slightly in the placebo
group) without statistically difference between two
groups probably due to small sample size (Table 2).
Notably, the change percent of a-CMAPs in motor
nerves was much less than 50 % indicating that OXIPN
is more sensory than motor neuropathy. The a-SAPs of
sural and ulnar nerves were decreased in proportion to
the baseline values in both the n-3 PUFA and placebo
groups. However, the decrease in a-SAP was much
greater in the latter group (Table 3). Argyriou et al.
reported that the only independent predictor for
unfavorable neurological outcomes was the decrease of
sural a-SAP >50 % in proportion to the baseline values
in cancer patients undergoing treatment with cisplatin
and paclitaxel [18]. In this study, DHA helped prevent
a sharp reduction in sural (−36.68 % vs. −100.00 %) and
ulnar (−18.28 % vs. −42.06 %) a-SAPs in the n-3 PUFAs
supplemented group and it improved the a-CMAP of
tibial, peroneal and ulnar motor nerves indicating the
beneficial effects of n-3 PUFAs (particularly DHA) on
both sensory and motor nerve conduction parameters.
Recently, dysfunction of axonal membrane Na+ and
Ca2+channels have been proposed as one of the mecha-
nisms underlying OXIPN as well as pain related to
chronic neuropathy [20, 21]. Therefore, finding an agent
capable of modulating ion channel activity may be
effective in preventing and reducing OXIPN, as some
evidences suggested that calcium channel blockers could
reduce acute OXIPN in patients receiving modified
FOLFOX chemotherapy regimen [22]. Previous studies
have shown that the anti-hypertensive as well as antiar-
rhythmic properties of n-3 PUFAs are due to their ability
to block voltage-gated sodium channels (VGSCs) and
voltage-gated calcium channels (VGCCs) reversibly in
arteries of muscle cells and cardiomyocytes without
frequency –dependent resistance [9, 23, 24]. N-3 PUFAs
can also block L-type VGCC and VGSCs of the pain
neurons involved in neuropathic pain as well [9].
Some studies revealed that an infusion of oxaliplatin in
CRC patients caused the release of inflammatory cyto-
kines such as interleukin 6(IL-6) and tumor necrosis
factor alpha (TNF-α) [25, 26] Interleukin-1beta (IL-1 β),
IL-6 and TNF-α (proinflammatory cytokines) and
prostaglandin E2 (PGE2) as an eicosanoid develop
neuropathic and inflammatory pain by their direct and
indirect impact on the central and peripheral nervous
systems (including DRG neurons, and glial cells) [9] .
Moreover, IL-1 β and TNF-α contribute to the rapid ex-
citation of nociceptors via the induction of Cyclooxygen-
ase 2 (COX-2) [27]. Serum levels of IL-6 and TNF-alpha
were decreased in n-3 PUFAs supplemented group,
although there was not a statistical difference with
placebo, possibly due to low dose and relatively short
period of n-3 PUFAs supplementation.
DHA has anti-neuroinflammatory properties both in
central and peripheral nervous system and it has been
attributed to the DHA efficacy in the prevention and
treatment of neurodegenerative disorders such as major
depression, Alzheimer’s and Parkinson’s diseases. Neuro-
protectin D1 (NPD1) is synthesized from DHA in the
body and it is an effective neuroprotective agent for the
prevention and treatment of confirmed neuropathic
pain. Noteworthy, the repeated administration of opioids
may cause antinociceptive drug tolerance and even
hyperalgesia, but DHA-derived NPD1do not create such
Fig. 2 Oxaliplatin induced peripheral neuropathy in the study groups
Table 1 General characteristics of the patients
Group
n-3 PUFAs (n = 36) Placebo (n = 35) P value
Gender (%)
Male 50 60
Female 50 40 .477*
Age (Year, mean ± SD) 54.14 ± 10.53 53.40 ± 15.70 .816**
Male 58.22 ± 8.02 54.48 ± 16.56
Female 50.06 ± 11.34 51.79 ± 14.78
BMIa (kg/m2,mean ± SD) 23.47 ± 3.40 23.22 ± 4.77 .806**
Male 22.43 ± 2.94 22.26 ± 2.91
Female 24.54 ± 4.68 24.91 ± 6.77
*P value is reported based on exact Chi-square test
**P value is reported based on Independent-Samples T Test
aBody mass index
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a resistance even after a long-term use of DHA [28–30].
It can promote axonal regeneration after chemotherapy-
induced peripheral neuropathy as a nerve growth factor.
NPD1 reduces gene expression of proinflammatory
cytokines (IL-1β and TNF-α) and COX-2 as well. Serum
levels of IL-6 and TNF-alpha were decreased in n-3
PUFAs supplemented group, although there was not a
statistical difference with placebo, possibly due to low
dose and relatively short period of n-3 PUFAs
supplementation.
In a number of randomized controlled trials using n-3
PUFAs, the rate of adverse events was not greater than
5 % with no considerable difference in frequency with
placebo groups and only some GI discomforts like nau-
sea and a fishy burp were reported. The standardized
preparation of n-3 PUFAs is in the capsular form and it
can be taken without considerable concern for inter-
action with other medications. We recommended to our
patients to take n-3 PUFAs capsules with meals and
keep them in the refrigerator. They had a strawberry
Table 2 Comparing the motor nerve conduction measurements between the two study groups
n-3 PUFAs (Mean ± SD) Placebo (Mean ± SD) Mean Difference 95 % CI, P-value
Tibial nerve
DML 1 (ms) 4.82 ± .81 5.80 ± 1.31 −.98 −1.50 to −.46, <.001*
DML 2a 4.60 ± .79 5.70 ± .95 − .68 − 1.18 to −.17, .009**
% Changec − 4.77 − 1.73
a-CMAP1(mV) 9.30 (5.62–13.72) 10.20 (5.60–15.30) – .696***
a-CMAP 2 10.20 (6.20–13.00) 6.10 (3.47–9.25) .003b
% Change 9.68 − 40.20
MCV 1(m/s) 45.81 ± 6.61 43.06 ± 5.08 2.74 −.05 to 5.54, .054*
MCV 2 45.67 ± 6.18 42.34 ± 4.68 1.86 − .52 to 4.25, .123**
% Change −.31 − 1.70
Peroneal nerve
DML 1 (ms) 4.34 ± .92 5.21 ± 1.44 −.87 −1.45 to −.30, .004*
DML 2 4.16 ± 1.04 5.02 ± 1.95 .08 − .78 to .94, .850**
% Change − 3.93 − 3.65
a-CMAP1(mV) 4.00 (3.00–4.60) 2.80 (1.90–5.20) – .238***
a-CMAP 2 4.40 (3.10–5.30) 2.90 (1.17–4.75) .217b
% Change 10.00 3.57
MCV 1(m/s) 47.59 ± 5.95 44.07 ± 6.91 3.51 .40 to 6.63, .028*
MCV 2 44.70 ± 5.30 43.60 ± 6.87 − 1.37 − 3.88 to 1.14, .278**
% Change − 6.07 −1.07
Ulnar nerve
DML 1 (ms) 3.12 ± .61 3.35 ± .59 −.23 −.51 to .060, .118*
DML 2 2.97 ± .55 3.33 ± .59 − .26 − .54 to .02, .073**
% Change − 4.81 − .60
aCMAP1(mV) 11.85 (9.40–14.30) 12.40 (10.80–13.10) – .394***
a-CMAP 2 13.10 (10.10–15.00) 10.75 (10.00–13.60) .033b
% Change 10.55 − 13.31
MCV 1(m/s) 63.01 ± 26.22 55.60 ± 10.89 7.42 −2.14 to 16.98, .126*
MCV 2 53.64 ± 16.72 53.98 ± 6.34 .07 −6.84 to 6.97, .984**
% Change − 14.87 − 2.90
DML distal motor latency, a-CMAP amplitude of compound muscle action potential, MCV motor conduction velocity
*P value is reported based on Independent-Samples T-Test
**P value is reported based on the analysis of covariance, adjusted for baseline values
***P value is reported based on the Mann–Whitney U Test
aOne month after the cessation of chemotherapy
bP value is reported based on the Mann–Whitney U Test (for changes of values during the intervention period)
cPercent change in proportion to the baseline values
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taste, and were well tolerated by the patients. The US
Food and Drug Administration (FDA) recommended
maximum levels of 3 g per day of n-3 PUFAs supple-
mentation [31]. In the current study, the total dose of n-
3 PUFAs administered was 1244.1 mg per day (640 mg:
54%DHA, 10 % EPA, t.i.d) which was far below the
maximum FDA recommended for more prudence. No
considerable side effects were reported by the patients.
Among a wide variety of compounds assessed for the
prevention or treatment of chemotherapy-induced
neuropathy, including vitamin E [32], Ca- Mg infusion
[33–35], amifostine, glutamine, and glutathione [36], the
Ca- Mg infusion was effective in this field. There is a
concern, however of interference with the clinical effi-
cacy of chemotherapy. Other compounds such as antide-
pressants, anticonvulsants [36] and green tea [37] had
limited effects or they were not studied in RCTs.
Lack of long-term follow up of the patients due to
high cost needed was one of the limitations of this study.
Therefore, coasting phenomenon and self-improvement
after the cessation of chemotherapy was not compared
between the two study groups. Moreover, placebo did
not smell fish oil and it may be considered as another
limitation of this study. Despite the relatively small
Table 4 Serum levels of proinflammatory cytokines in two groups of patients
n-3 PUFAs (Median, percentile 25–75) Placebo (Median, percentile 25-75) P-value
IL-6a 1(pg/ml) 28.70 (20.50–42.60) 21.50 (15.20–51.10) .194*
IL-6 2 22.70 (17.10–30.45) 25.50 (16.80–55.40) .396**
% Change −20.91 18.60
TNF-αb 1(pg/ml) 4.00 (3.60–5.25) 4.30 (3.60–5.60) .218*
TNF-α 2 3.50 (3.15–4.97) 4.35 (3.15–4.97) .097**
% Change −12.50 1.16
hs-CRP 1(mg/l) 2.95 (.92–7.30) 2.88 (1.31–15.40) .505*
hs-CRP 2 1.15 (.82–2.32) 1.29 (.82–2.90) .390**
% Change −61.02 −55.21
*P value is reported based on the Mann–Whitney U Test
**P value is reported based on the Mann–Whitney U Test (for changes of values during the intervention period)
aInterleukin-6
bTumor necrosis factor-α
Table 3 Comparing the sensory nerve conduction measurements between the two study groups
n-3 PUFAs (Mean ± SD) Placebo (Mean ± SD) Mean Difference 95 % CI P-value
Sural nerve
aSAP1(μV) 9.95 (5.52–16.40) 5.50 (3.40–14.10) – .033***
aSAP 2a 6.30 (4.60–10.30) .00 (.00–7.32) .052b
%Changec − 36.68 − 100.00
SCV1(m/s) 43.99 ± 15.17 44.82 ± 6.27 −.83 −6.44 to 4.78, .766*
SCV 2 42.29 ± 15.51 29.67 ± 13.01 12.24 2.22 to 22.26, .018**
% Change −3.84 − 33.80
Ulnar nerve
aSAP1(μV) 27.90 (16.82–42.77) 17.50 (12.40–35.50) – .144***
a- SAP 2 22.80 (6.20–27.30) 10.14 (2.70–18.60) .430b
% Change − 18.28 − 42.06
SCV1(m/s) 51.66 ± 8.34 50.15 ± 8.23 1.50 −2.51 to 5.52, .457*
SCV 2 44.08 ± 11.14 42.62 ± 7.26 .98 −4.61 to 6.57, .726**
% Change − 14.66 − 15.01
a-SAP sensory action potential amplitude, SCV sensory conduction velocity
*P value is reported based on Independent-Samples T-Test
**P value is reported based on the analysis of covariance, adjusted for baseline values
***P value is reported based on the Mann–Whitney U Test
aOne month after the cessation of chemotherapy
bP value is reported based on the Mann–Whitney U Test (for changes of values during the intervention period)
cPercent change in proportion to the baseline values
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sample size of this study (we could not run a multicenter
RCT, because of some problems in coordination
between centers), the incidence and severity of OXIPN
was different between the n-3 PUFAs and placebo
groups, maybe due to the strong effect of DHA on the
peripheral nervous system of the patients through the
different mechanisms pointed out here and other
presently unknown reasons, as the precise mechanism of
OXIPN is not clear.
Conclusions
OXIPN will continue for a long time in patients who
received oxaliplatin and it has a remarkable influence on
the patients’ quality of life [1, 7]. As the survival of this
group of patients is increased significantly worldwide,
finding an effective prophylactic or symptomatic therapy
for OXIPN should be of special interest [2, 5]. In this
study, n-3 PUFAs supplementation could reduce the
incidence and severity of OXIPN in patients with colon
cancer. It is well tolerated by patients because of few if
any complications. Therefore, given the low-cost and
safety of DHA, it can be recommended as a prophylactic
and therapeutic agent for OXIPN. Further studies with
larger sample size and longer follow-up are needed to
confirm these findings.
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